… safe harbour against later double patenting attacks. Voluntary divisionals, filed … to overcome obviousness-type double patenting.11 Restriction requirements compel applicants … 193 [Abbott]. 7. Biogen and Acorda Therapeutics Inc v Taro Pharmaceuticals Inc …

… a substantial issue of patent law. Acorda Therapeutics Inc. v. Alkermes … , Hughes, Stark, JJ.) Acorda Therapeutics, the developer of Ampyra®, a … was unenforceable after the patent’s expiration. However, … without judicial interpretation of patent law. The Federal …

… and Reasoning Regeneron Pharmaceuticals filed patent infringement suits against Samsung … found this argument unavailing, citing Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc … words, if the later patent is not patentably distinct, it should terminate …

… “ACORQ” ticker symbol. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …

… the “pink sheets”). About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …

… and Exchange Commission. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …

… Corporation (“Shibuya”) for patent infringement resulting in a … applying its reasoning from Acorda Therapeutics Inc. v. Mylan … IPRs concerning expired patents.   The challenged patent expired before the … rights to the patentee. Although a patentee has fewer …

… for more information. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …

… at this time. About Acorda Therapeutics  Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; the ability to realize … by law.   Financial Statements Acorda Therapeutics, Inc. Condensed Consolidated Balance …

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … of saliva or spit. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …